Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.MicroDose Technologies has announced that the first clinical milestone in its collaboration with Merck & Co, through a Merck affiliate, has been achieved, triggering the first payment under the global license agreement for MicroDose's dry powder inhaler technology announced in March 2008.
Subscribe to our email newsletter
This milestone signals the initiation by Merck of a Phase I clinical study of an investigational compound using the MicroDose dry powder inhaler (DPI) technology.
As previously announced, Merck will fund development and commercialization of products that employ MicroDose’s DPI technology for the administration of Merck compounds.
In addition to the upfront payment received upon commencement of the collaboration, MicroDose is eligible for additional milestone payments on this product and for the development of other products and royalties on revenues from all products developed under the license.
David Byron, vice president of R&D at MicroDose, said: “Achieving this milestone with Merck so quickly is a strong indicator of the excellent working relationship that underpins this collaboration.”